Your browser is no longer supported. Please, upgrade your browser.
ADMA Biologics, Inc.
Index- P/E- EPS (ttm)-0.79 Insider Own0.50% Shs Outstand115.66M Perf Week-5.63%
Market Cap201.07M Forward P/E- EPS next Y-0.34 Insider Trans0.00% Shs Float104.02M Perf Month0.00%
Income-74.90M PEG- EPS next Q-0.15 Inst Own41.90% Short Float11.21% Perf Quarter-13.71%
Sales48.10M P/S4.18 EPS this Y1.00% Inst Trans0.00% Short Ratio4.94 Perf Half Y-44.07%
Book/sh0.97 P/B1.56 EPS next Y40.40% ROA-36.30% Target Price- Perf Year-55.19%
Cash/sh0.47 P/C3.24 EPS next 5Y- ROE-85.80% 52W Range1.38 - 3.71 Perf YTD-22.56%
Dividend- P/FCF- EPS past 5Y12.60% ROI- 52W High-59.30% Beta1.24
Dividend %- Quick Ratio3.90 Sales past 5Y42.50% Gross Margin-29.50% 52W Low9.42% ATR0.07
Employees406 Current Ratio8.40 Sales Q/Q56.90% Oper. Margin- RSI (14)41.15 Volatility4.56% 4.95%
OptionableYes Debt/Eq0.83 EPS Q/Q39.10% Profit Margin- Rel Volume0.37 Prev Close1.58
ShortableYes LT Debt/Eq0.83 EarningsMay 12 AMC Payout- Avg Volume2.36M Price1.51
Recom1.80 SMA20-2.20% SMA50-8.27% SMA200-23.32% Volume869,716 Change-4.43%
Jun-04-19Initiated Jefferies Buy $8
Apr-15-19Reiterated H.C. Wainwright Buy $10 → $13
Feb-07-19Resumed H.C. Wainwright Buy $10
Dec-11-17Reiterated Maxim Group Buy $13 → $8
Nov-14-17Upgrade Raymond James Mkt Perform → Outperform
Jan-23-17Upgrade Maxim Group Hold → Buy $13
Aug-01-16Downgrade Maxim Group Buy → Hold
Jul-25-16Reiterated Maxim Group Buy $24 → $14
May-13-15Reiterated Maxim Group Buy $18 → $24
Dec-08-14Initiated Oppenheimer Outperform $20
Dec-01-14Reiterated Maxim Group Buy $16 → $18
Aug-04-21 07:00AM  
Jul-28-21 03:03PM  
Jul-21-21 01:23AM  
Jul-20-21 07:00AM  
Jun-14-21 07:00AM  
May-26-21 07:00AM  
May-22-21 03:08AM  
May-12-21 09:00PM  
May-10-21 08:39AM  
May-06-21 01:27AM  
May-05-21 07:00AM  
Apr-28-21 01:54PM  
Apr-26-21 08:00AM  
Apr-21-21 11:43AM  
Apr-13-21 08:00AM  
Mar-25-21 07:30PM  
Mar-18-21 08:00AM  
Mar-04-21 12:30PM  
Mar-03-21 08:00AM  
Feb-26-21 08:00AM  
Feb-22-21 08:00AM  
Feb-04-21 11:49PM  
Feb-01-21 08:00AM  
Jan-26-21 08:00AM  
Jan-19-21 08:00AM  
Jan-04-21 08:00AM  
Dec-21-20 11:24PM  
Dec-19-20 11:26AM  
Dec-16-20 04:15PM  
Dec-09-20 10:33AM  
Dec-08-20 11:35AM  
Dec-01-20 07:00AM  
Nov-10-20 07:00AM  
Nov-07-20 07:11AM  
Nov-06-20 09:31AM  
Nov-05-20 06:55PM  
Oct-29-20 07:00AM  
Oct-28-20 12:55PM  
Oct-21-20 07:00AM  
Oct-14-20 08:43AM  
Oct-07-20 09:16AM  
Oct-06-20 10:29AM  
Oct-01-20 08:41AM  
Sep-14-20 11:56AM  
Sep-09-20 07:00AM  
Sep-08-20 06:41AM  
Sep-03-20 07:00AM  
Sep-02-20 07:00AM  
Aug-25-20 08:55AM  
Aug-24-20 01:30PM  
Aug-10-20 01:03PM  
Aug-05-20 07:25PM  
Aug-03-20 07:34AM  
Jul-29-20 07:00AM  
Jul-07-20 08:55AM  
Jul-06-20 07:00AM  
Jul-03-20 10:13AM  
Jun-23-20 12:49PM  
Jun-09-20 03:21PM  
Jun-01-20 09:44AM  
May-27-20 07:00AM  
May-21-20 07:00AM  
May-07-20 10:30AM  
May-06-20 08:15PM  
May-01-20 06:13AM  
Apr-29-20 07:00AM  
Apr-03-20 03:48AM  
Mar-17-20 06:12AM  
Mar-12-20 04:05PM  
Mar-05-20 06:59AM  
Mar-03-20 07:00AM  
Feb-24-20 07:00AM  
Feb-13-20 05:07AM  
Feb-11-20 04:20PM  
Feb-07-20 07:32AM  
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DEMSKI MARTHA JDirectorSep 11Buy2.292,2005,0384,200Sep 14 08:00 AM
Grossman Jerrold BDirectorSep 10Buy2.225,00011,100160,864Sep 11 08:00 AM
Mond JamesEVP, CSO and CMOSep 08Buy2.204,0008,80073,174Sep 10 08:01 AM
Grossman Adam SPresident and CEOSep 08Buy2.244,0008,960176,098Sep 10 08:00 AM
Grossman Jerrold BDirectorAug 21Buy2.565,30013,586155,864Aug 25 08:00 AM
DEMSKI MARTHA JDirectorAug 13Buy2.882,0005,7602,000Aug 14 08:00 AM
Grossman Jerrold BDirectorAug 12Buy2.8910,20029,499150,564Aug 13 08:01 AM
LENZ BRIANEVP, CFOAug 11Buy2.964,00011,86076,142Aug 12 08:02 AM
Grossman Adam SPresident and CEOAug 11Buy2.971,0002,970172,098Aug 12 08:02 AM
Grossman Adam SPresident and CEOAug 10Buy3.065,00015,290171,098Aug 12 08:02 AM
Mond JamesEVP, CSO and CMOAug 10Buy2.887,00020,15069,174Aug 12 08:01 AM